HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) today announced that it has entered into a license agreement with Alexion, AstraZeneca Rare Disease (“Alexion”), for ...

In its bid to develop epilepsy treatments that can overcome the notoriously tricky blood-brain barrier, Angelini Pharma has pledged to pay JCR Pharmaceuticals over $500 million in biobucks. Angelini, ...

JCR Pharmaceuticals has achieved proof of concept for its gene therapy technology—just in time to lose partner Takeda as the pharma pivots away from adeno-associated viruses. The Japanese companies ...

While there are now a ton of electric skateboards on the market, almost all of them are controlled by a handheld remote. The Chinese-made JCR Board, however, is controlled by shifting your weight – ...

- Strategic partnership utilizes JCR’s J-Brain Cargo® to develop a novel blood-brain barrier-penetrating therapy targeting a pathological driver of Alzheimer’s disease - HYOGO, Japan, July 15, ...

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today ...

– Additional Posters Underscore Broad Potential of J-Brain Cargo ® Platform, Including Preclinical Data for Pabinafusp Alfa in MPS II and Nonclinical Data for JR-446 in MPS IIIB – HYOGO, ...

It’s hard for a financier to differentiate itself in today’s market. JCR Capital’s Jay Rollins said his firm’s “prolific” equity approach and the deep track record of its co-founders sets the firm ...

MANILA, Philippines — Tokyo-based Japan Credit Rating Agency Ltd. (JCR) has affirmed the A-credit rating and stable outlook of the Philippines despite the delayed economic recovery due to mobility ...